| __timestamp | Apellis Pharmaceuticals, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 15411924 |
| Thursday, January 1, 2015 | 13730311 | 22593274 |
| Friday, January 1, 2016 | 22978599 | 33173050 |
| Sunday, January 1, 2017 | 40303878 | 62224159 |
| Monday, January 1, 2018 | 105285576 | 95607434 |
| Tuesday, January 1, 2019 | 220968770 | 221269028 |
| Wednesday, January 1, 2020 | 299921000 | 400745069 |
| Friday, January 1, 2021 | 420869000 | 580520000 |
| Saturday, January 1, 2022 | 387236000 | 663366000 |
| Sunday, January 1, 2023 | 354387000 | 755113687 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, argenx SE and Apellis Pharmaceuticals, Inc. have demonstrated a strategic focus on R&D, with argenx SE consistently outpacing its competitor. From 2014 to 2023, argenx SE increased its R&D expenses by nearly 4,800%, reaching a peak in 2023. In contrast, Apellis Pharmaceuticals saw a growth of approximately 4,100% over the same period. This significant investment underscores argenx SE's aggressive pursuit of groundbreaking therapies, while Apellis Pharmaceuticals maintains a robust commitment to innovation. As the biotech landscape evolves, these companies' R&D strategies will likely play a pivotal role in shaping their future success.
Comparing Innovation Spending: AstraZeneca PLC and Apellis Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Regeneron Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
R&D Insights: How GSK plc and Apellis Pharmaceuticals, Inc. Allocate Funds
argenx SE or Ascendis Pharma A/S: Who Invests More in Innovation?
Research and Development Expenses Breakdown: argenx SE vs Lantheus Holdings, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alkermes plc
R&D Spending Showdown: argenx SE vs Rhythm Pharmaceuticals, Inc.
Research and Development Investment: argenx SE vs Agios Pharmaceuticals, Inc.
Comparing Innovation Spending: argenx SE and Supernus Pharmaceuticals, Inc.
argenx SE or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Apellis Pharmaceuticals, Inc. and Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for Apellis Pharmaceuticals, Inc. and Evotec SE